Cargando…

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Elucidating the characteristics of human immune response against SARS-CoV-2 is of high priority and relevant for determining vaccine strategies. We report the results of a follow-up evaluation of anti-SARS-CoV-2 antibodies in 148 convalescent plasma donors who participated in a phase 2 study at a me...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Stellas, Dimitris, Rosati, Margherita, Sergentanis, Theodoros N., Hu, Xintao, Politou, Marianna, Pappa, Vassiliki, Ntanasis-Stathopoulos, Ioannis, Karaliota, Sevasti, Bear, Jenifer, Donohue, Duncan, Pagoni, Maria, Grouzi, Elisavet, Korompoki, Eleni, Pavlakis, George N., Felber, Barbara K., Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128693/
https://www.ncbi.nlm.nih.gov/pubmed/34053848
http://dx.doi.org/10.1016/j.ejim.2021.05.010
Descripción
Sumario:Elucidating the characteristics of human immune response against SARS-CoV-2 is of high priority and relevant for determining vaccine strategies. We report the results of a follow-up evaluation of anti-SARS-CoV-2 antibodies in 148 convalescent plasma donors who participated in a phase 2 study at a median of 8.3 months (range 6.8–10.5 months) post first symptom onset. Monitoring responses over time, we found contraction of antibody responses for all four antigens tested, with Spike antibodies showing higher persistence than Nucleocapsid antibodies. A piecewise linear random-effects multivariate regression analysis showed a bi-phasic antibody decay with a more pronounced decrease during the first 6 months post symptoms onset by analysis of two intervals. Interestingly, antibodies to Spike showed better longevity whereas their neutralization ability contracted faster. As a result, neutralizing antibodies were detected in only 76% of patients at the last time point. In a multivariate analysis, older age and hospitalization were independently associated with higher Spike, Spike-RBD, Nucleocapsid, N-RBD antibodies and neutralizing antibody levels. Results on persistence and neutralizing ability of anti-SARS-CoV-2 antibodies, especially against Spike and Spike-RBD, should be considered in the design of future vaccination strategies.